Life sciences companies in fields such as biotechnology, pharmaceuticals and biomedical technologies had a banner financing year in 2010, in spite of the fact that the health care sector was among the worst performing sectors in the stock market.

Life sciences companies in the U.S. raised $9 billion in financing from venture capitalists, more than double the $4 billion they raised in 2009, according to Burrill & Company, a San Francisco-based life sciences investment bank and data provider. However, most of the capital was in late stage financings: venture capitalists being forced to put up large sums of money to keep alive cash-burning companies that couldn’t make IPO exits or be acquired. The real boost ....



Read More: life sciences · financing · global markets · biotechnology · pharmaceuticals · biomedical technology